BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15862970)

  • 1. The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites.
    Raobaikady B; Day JM; Purohit A; Potter BV; Reed MJ
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):229-37. PubMed ID: 15862970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of oestrone sulphatase activity by tibolone and its metabolites.
    Purohit A; Malini B; Hooymans C; Newman SP
    Horm Metab Res; 2002 Jan; 34(1):1-6. PubMed ID: 11832993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tibolone and its delta-4, 7alpha-methyl norethisterone metabolite are reversible inhibitors of human aromatase.
    Raobaikady B; Parsons MF; Reed MJ; Purohit A
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):154-60. PubMed ID: 17467267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-selectivity: the mechanism of action of tibolone.
    Kloosterboer HJ
    Maturitas; 2004 Aug; 48 Suppl 1():S30-40. PubMed ID: 15337246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.
    Woo LW; Howarth NM; Purohit A; Hejaz HA; Reed MJ; Potter BV
    J Med Chem; 1998 Mar; 41(7):1068-83. PubMed ID: 9544207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
    Utsumi T; Leese MP; Chander SK; Gaukroger K; Purohit A; Newman SP; Potter BV; Reed MJ
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):219-27. PubMed ID: 15862969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-selective effects of tibolone on the breast.
    Kloosterboer HJ
    Maturitas; 2004 Sep; 49(1):S5-S15. PubMed ID: 15351102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro.
    Stute P; Götte M; Kiesel L
    Breast Cancer Res Treat; 2008 Apr; 108(3):363-74. PubMed ID: 17546497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro.
    Vanhoecke BW; Bracke ME; Kloosterboer HJ; Depypere HT
    Maturitas; 2006 Jun; 54(3):229-37. PubMed ID: 16581209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tibolone: a compound with tissue specific inhibitory effects on sulfatase.
    de Gooyer ME; Kleyn GT; Smits KC; Ederveen AG; Verheul HA; Kloosterboer HJ
    Mol Cell Endocrinol; 2001 Oct; 183(1-2):55-62. PubMed ID: 11604225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor.
    Reed JE; Woo LW; Robinson JJ; Leblond B; Leese MP; Purohit A; Reed MJ; Potter BV
    Biochem Biophys Res Commun; 2004 Apr; 317(1):169-75. PubMed ID: 15047163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects.
    Schatz F; Kuczynski E; Kloosterboer HJ; Buchwalder L; Tang C; Krikun G; Lockwood CJ
    Steroids; 2005 Nov; 70(12):840-5. PubMed ID: 16011840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells.
    Chetrite G; Kloosterboer HJ; Pasqualini JR
    Anticancer Res; 1997; 17(1A):135-40. PubMed ID: 9066643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives.
    Phan CM; Liu Y; Kim BM; Mostafa Y; Taylor SD
    Bioorg Med Chem; 2011 Oct; 19(20):5999-6005. PubMed ID: 21925885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of stable transfection of human fetal osteoblast cells with estrogen receptor-alpha on regulation of gene expression by tibolone.
    Maran A; Shogren K; Zhang M; Yaszemski MJ; Hefferan TE; Spelsberg TC; Kloosterboer HJ; Turner RT
    Bone; 2006 Sep; 39(3):523-9. PubMed ID: 16707283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.
    Foster PA; Newman SP; Chander SK; Stengel C; Jhalli R; Woo LL; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2006 Sep; 12(18):5543-9. PubMed ID: 17000691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone.
    Falany JL; Falany CN
    Steroids; 2006 Oct; 71(10):880-5. PubMed ID: 16857224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy.
    Purohit A; Chander SK; Woo LW; Parsons MF; Jhalli R; Potter BV; Reed MJ
    Anticancer Res; 2008; 28(3A):1517-23. PubMed ID: 18630506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days.
    Kloosterboer HJ; Löfgren L; von Schoulz E; von Schoultz B; Verheul HA
    Reprod Sci; 2007 Feb; 14(2):151-9. PubMed ID: 17636226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.
    Foster PA; Chander SK; Parsons MF; Newman SP; Woo LW; Potter BV; Reed MJ; Purohit A
    Breast Cancer Res Treat; 2008 Sep; 111(1):129-38. PubMed ID: 17914670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.